Author: perrin - Page 4 - Nanostics Precision Health

Press Release: Nanostics Receives CE Mark for its ClarityDX Prostate® Test to Detect Clinically Significant Prostate Cancer

perrin2022-08-23T12:18:30+00:00

Nanostics’ biomarker and machine learning-powered test, ClarityDX Prostate®, received a CE-IVD Mark.
A CE-IVD Mark is required for all in vitro diagnostic (IVD) devices to be placed in the European Economic Area, Iceland, Norway, and Liechtenstein and allows Nanostics to market and sell ClarityDX Prostate® in these countries.
The ClarityDX Prostate® test provides patients and physicians with an accurate prediction of clinically significant prostate cancer to support decision-making and improve health outcomes for men suspected of having prostate cancer.

Press Release: Nanostics Receives CE Mark for its ClarityDX Prostate® Test to Detect Clinically Significant Prostate Cancerperrin2022-08-23T12:18:30+00:00

Press Release: Nanostics Announces the Launch of its Bladder Cancer Clinical Study Identifying Disease Predictors for Early Detection of Bladder Cancer

perrin2022-07-20T13:09:06+00:00

Clinical study launched in June 2022 with patient recruitment in Alberta with plans to expand to further sites across North America.
The aim of the study is to validate a novel and minimally invasive liquid biopsy test for bladder cancer diagnosis using Nanostics’ ClarityDX® diagnostic platform.
The study is supported in part by the Alberta Innovates AICE-Concepts Program with a $600,000 award to Dr. John Lewis, Bird Dogs Chair in Translational Cancer Research at the University of Alberta.

Press Release

Press Release: Nanostics Announces the Launch of its Bladder Cancer Clinical Study Identifying Disease Predictors for Early Detection of Bladder Cancerperrin2022-07-20T13:09:06+00:00

Press Release: Nanostics Announces Study Data Supporting ClarityDX Prostate as a Reflex Test to Predict Clinically Significant Prostate Cancer

perrin2022-06-30T12:14:03+00:00

Real-world data shows that at a 94% sensitivity level for prostate cancer ClarityDX Prostate® is 147% more specific than the PSA test for predicting clinically significant prostate cancer. Using ClarityDX Prostate® as a reflex test vs. PSA test alone could have resulted in 37% fewer unnecessary biopsies.

Press Release

Press Release: Nanostics Announces Study Data Supporting ClarityDX Prostate as a Reflex Test to Predict Clinically Significant Prostate Cancerperrin2022-06-30T12:14:03+00:00

Liquid biopsy EV analysis with small particle flow cytometry

perrin2022-09-02T06:29:31+00:00

Click here for CYTO 2022 POSTER PRESENTATION

Click here for CYTO 2022 SLIDE PRESENTATION

Small particle flow cytometry using 3 light scatter detectors enhances extracellular vesicle analysis in liquid biopsies, highlighting the potential to segregate EVs by refractive index

Pink, Desmond, Basu, Arghya, Valencia, Juliana, Pham, Diana, and Lewis, J.D.

Extracellular vesicle analysis using “small particle” flow cytometry would be greatly enhanced if data from materials of different refractive index (RI) could be segregated. Likewise, relative sizing of EVs using small particle flow cytometry is confounded by the influence of RI on light scatter. Beads of different composition and refractive index scatter light differently, so that small beads of high RI and large beads of lower RI can have overlapping signals on a two dimension light scatter plot. As particle size decreases, light scatter intensity profiles eventually merge regardless of refractive index. In this project, we aimed to demonstrate graphically, (1) the enhancement of EV flow analysis when using an additional angle of light scatter collection (medium angle of light scatter, MALS) to identify different sample components (e.g. lipids, protein, extracellular vesicles) and (2) the practical reality of sample component overlap at different particle sizes.

Nanostics CSO Desmond Pink will be presenting this work at CYTO 2022, June 3-7, in Philadelphia, US.
CYTO 2022 MOVING FORWARD
Empowering Scientists. Advancing Cytometry.

Liquid biopsy EV analysis with small particle flow cytometryperrin2022-09-02T06:29:31+00:00

STARTUP TNT Life Sciences Summit Finale

perrin2022-03-17T18:21:48+00:00

LIFE SCIENCES SUMMIT FINALE

Date: Thu, March 17, 2022 at 3:30 PM – 7:30 PM MDT

Venue: Online and in-person for more details and to register go to Eventbrite.

5 Pitches. 1 massive Zoom party. 4 in-person afterparties.

CCO Colin Coros will take part in the pre-game show: “Get to Know the Investors, What’s Happening in Life Sciences Anyway, and Why I’m Building It Here”

STARTUP TNT Life Sciences Summit Finaleperrin2022-03-17T18:21:48+00:00

Invest in the West presented by Amplitude Ventures

perrin2022-03-10T23:07:42+00:00

Date: Thursday, March 10, 2022

Venue: Virtual – click on the Address button for tickets and agenda

Nanostics COO Catalina Vasquez will be presenting in the Diagnostics, Digital Health, Medical Devices, Technology session.
#InvestWest will bring stakeholders in the #lifesciences sector together with investor-ready companies for a day of presentations and valuable discussions.

Address

Invest in the West presented by Amplitude Venturesperrin2022-03-10T23:07:42+00:00

Riyadh Global Summit For AI In Healthcare

perrin2022-03-10T23:23:43+00:00

Date: March 5-6, 2022

Venue: The Kingdom of Saudi Arabia & Virtual

The Riyadh Global Summit For Artificial Intelligence In Healthcare brought leading AI scientists, Pharma executives, and business leaders from around the world together to explore the potential of AI, machine learning, and deep learning in healthcare. CEO John Lewis spoke on March 5 about AI-Driven Non-Invasive Diagnostic Tests for Cancer and our ClarityDX platform technology.

Click here for the Event Highlights.

Address

Riyadh Global Summit For AI In Healthcareperrin2022-03-10T23:23:43+00:00

About perrin

Follow Us

Contact Us